Aspira Women's Health Faces Delisting Notice
Ticker: AWHL · Form: 8-K · Filed: Feb 14, 2025 · CIK: 926617
Sentiment: bearish
Topics: delisting, listing-standards, compliance
TL;DR
Aspira Women's Health got a notice about possibly being delisted. Big trouble ahead?
AI Summary
Aspira Women's Health Inc. filed an 8-K on February 14, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of February 11, 2025. The company, formerly known as Vermillion, Inc., Ciphergen Biosystems Inc., and Abiotic Systems, is incorporated in Delaware and headquartered in Austin, Texas.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the company's liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued trading and investor confidence.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- February 11, 2025 (date) — Date of earliest event reported
- February 14, 2025 (date) — Date of report
- Vermillion, Inc. (company) — Former company name
- Ciphergen Biosystems Inc (company) — Former company name
- Abiotic Systems (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- Austin, Texas (location) — Business address city and state
FAQ
What specific listing rule or standard has Aspira Women's Health Inc. failed to satisfy?
The filing states that the company received a notice of delisting or failure to satisfy a continued listing rule or standard, but does not specify which rule or standard was violated.
What is the date of the notice of delisting or failure to satisfy a continued listing rule?
The earliest event reported, which includes the notice, is dated February 11, 2025.
When was this Form 8-K filed with the SEC?
This Form 8-K was filed on February 14, 2025.
What were some of Aspira Women's Health Inc.'s former company names?
Aspira Women's Health Inc. was formerly known as Vermillion, Inc., Ciphergen Biosystems Inc, and Abiotic Systems.
Where is Aspira Women's Health Inc. incorporated and headquartered?
The company is incorporated in Delaware and its business address is in Austin, Texas.
Filing Stats: 630 words · 3 min read · ~2 pages · Grade level 12.8 · Accepted 2025-02-14 16:30:26
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AWH Nasdaq Capital Market
- $1.53 — 's Common Stock, at a purchase price of $1.53 per share of Common Stock and accompany
- $1.47 — securities for the Private Placement of $1.47 per share plus $0.125 attributable to t
- $0.125 — ivate Placement of $1.47 per share plus $0.125 attributable to the value of the warran
- $1.595 — or purposes of Listing Rule 5625(c) was $1.595. Since the shares and warrants sold in
Filing Documents
- form8-k.htm (8-K) — 25KB
- 0001493152-25-006890.txt ( ) — 195KB
- awh-20250211.xsd (EX-101.SCH) — 3KB
- awh-20250211_lab.xml (EX-101.LAB) — 33KB
- awh-20250211_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing . On June 30, 2024, Aspira Women's Health Inc. (the "Company") entered into a securities purchase agreement (the "Purchase Agreement") with certain existing accredited shareholders and Company insiders for the issuance and sale in a private placement (the "Private Placement") of (i) 1,264,739 shares of the Company's common stock (the "Common Stock") and (ii) warrants (the "Common Warrants") to purchase up to 1,264,739 shares of the Company's Common Stock, at a purchase price of $1.53 per share of Common Stock and accompanying warrants. On February 11, 2025, the Company received written notice (the "Notice") from the Nasdaq Stock Market, LLC ("Nasdaq") that based on the closing bid price per share immediately preceding entering into a binding agreement to issue the securities for the Private Placement of $1.47 per share plus $0.125 attributable to the value of the warrants, the market value of the transaction for purposes of Listing Rule 5625(c) was $1.595. Since the shares and warrants sold in the private placement were issued below the market value, and the Company failed to obtain shareholder approval, the Company violated Listing Rule 5635(c). Accordingly, this matter served as an additional basis for delisting the Company's securities from The Nasdaq Stock Market. Subsequently, on February 11, 2025, the Company completed amendments to the warrants prohibiting exercise until shareholder approval has been obtained. As a result, Staff has determined that the Company has regained compliance with Listing Rule 5635(c) and subject to the disclosure requirements below, this matter is now closed. There can be no assurance that the Company will be successful in maintaining its listing of its common stock on the Nasdaq Capital Market.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ASPIRA WOMEN'S HEALTH INC. Date: February 14, 2025 By: /s/ Mike Buhle Mike Buhle Chief Executive Officer